Predicting the benefit of therapies for patients with triple negative breast cancer

Lead researcher

Dr Belinda Parker

Dr Belinda Parker

Institution
La Trobe University

Tumour type:
Breast

Years funded
2017-2019

Project description

This project explores the importance of an immune pathway in response to current and emerging breast cancer therapies. The results may lead to individualised treatment for patients with triple negative breast cancers. 

What are you trying to achieve?

There are currently limited treatment options for patients with triple negative breast cancer (TNBC). We have found that specific immune pathways are lost in TNBC, possibly promoting an immune suppressed environment. Importantly, TNBC patients that have intact immune signals have a much better progrnosis. We aim to test the potential of specific immune regulators as prognostic markers and markers of response to conventional and immune targeted therapies in TNBC.

What is your personal motivation?

Cancer directly or indirectly impacts so many people. Although the survival rates for breast cancer patients are quite high, this disease remains the second leading cause of cancer-related deaths in Australian women.

I am motivated to find better therapies for some breast cancer patients to reduce this mortality whilst also finding ways to spare other patients the toxic side effects of treatments that won't benefit them.

Ultimately, I want to develop prognostic markers to reduce the uncertainty for cancer patients and allow individualised therapeutic approaches that will decrease the risk of losing loved ones living with this disease. 

Project timeline

2017  2018 
2019 

Measure the association of tumour interferon regulator expression with tumour immunogenicity in TNBC

Test the consequences of altered tumour immune regulator expression on metastasis-free survival and therapeutic response in syngeneic models of TNBC 

 
  

Measure the association of tumour interferon regulator expression with tumour immunogenicity in TNBC

Test the consequences of altered tumour immune regulator expression on metastasis-free survival and therapeutic response in syngeneic models of TNBC    

Test the consequences of altered tumour immune regulator expression on metastasis-free survival and therapeutic response in syngeneic models of TNBC  

"Ultimately, I want to develop progrnostic markers to reduce the uncertainty for cancer patients and targeted therapies that will decrease the risk of losing mothers, daughters, sisters and friends living with this disease."

Collaborators

A/Prof Phil Darcy